Antonio Marzocchi

Showing 1-13 of 13 articles

Interventions for valvular disease

Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses

Landes U, Dvir D, Schoels W, Tron C, Ensminger S, Simonato M, Schäfer U, Bunc M, Aldea GS, Cerillo A, Windecker S, Marzocchi A, Andreas M, Amabile N, Webb J, Kornowski R

May 20, 2019 | 10.4244/EIJ-D-18-00752

Interventions for valvular disease

How should I treat an unexpected deadlock at the time of transcatheter aortic valve prosthesis implantation?

Dall’Ara G, Moretti C, Marrozzini C, Taglieri N, Saia F, Marzocchi A, Witkowski A, Kahlert P, Hildebrandt H, Lind A, Janosi R, Rassaf T

June 2, 2017 | 10.4244/EIJ-D-16-00902

Transcatheter aortic valve implantation for severe autograft regurgitation after Ross operation

Saia F, Galie N, Laborde J-C, Di Bartolomeo R, Manes A, Marzocchi A

May 20, 2014 | 10.4244/EIJV10I1A21

Percutaneous treatment of paravalvular leaks after transcatheter aortic valve implantation with the CoreValve self-expanding bioprosthesis

Saia F, Marrozzini C, Moretti C, Bordoni B, Ciuca C, Marzocchi A

June 28, 2013 | 10.4244/EIJV9I2A47

Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era

Saia F, Marrozzini C, Ciuca C, Guastaroba P, Taglieri N, Palmerini T, Bordoni B, Moretti C, Dall’Ara G, Branzi A, Marzocchi A

April 19, 2013 | 10.4244/EIJV8I12A212

Regional differences and Italian charter to expand the primary angioplasty service

De Luca L, Cremonesi A, Marzocchi A, Guagliumi G

August 25, 2012 | 10.4244/EIJV8SPA14

The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation

Saia F, Marrozzini C, Moretti C, Ciuca C, Taglieri N, Bordoni B, Dall’Ara G, Alessi L, Lanzillotti V, Bacchi-Reggiani M, Branzi A, Marzocchi A

October 28, 2011 | 10.4244/EIJV7I6A115

Pre-hospital ECG in patients undergoing primary percutaneous interventions within an integrated system of care: reperfusion times and long-term survival benefits

Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Alessi L, Nardini P, Reggiani M-L, Guastaroba P, De Palma R, Grilli R, Picoco C, Gordini G, Branzi A

August 30, 2011 | 10.4244/EIJV7I4A74

Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation

Varani E, Guastaroba P, Di Tanna G, Saia F, Balducelli M, Campo G, Vignali L, Rossi R, Manari A, Piovaccari G, De Palma R, Marzocchi A

April 12, 2010

Sex-related differences in patients undergoing percutaneous unprotected left main stenting

Sheiban I, La Spina C, Cavallero E, Biondi-Zoccai G, Colombo F, Palmerini T, Marzocchi A, Tamburino C, Margheri M, Vecchi G, Sangiorgi G, Santarelli A, Bartorelli A, Briguori C, Vignali L, di Pede F, Ramondo A, Fantoni C, De Carlo M, Falsini G, Benassi A, Palmieri C, Filippone V, Sangiorgi D, De Servi S

February 25, 2010

Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories

Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C

January 15, 2010

Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry

Saia F, Piovaccari G, Manari A, Guastaroba P, Vignali L, Varani E, Santarelli A, Benassi A, Liso A, Campo G, Tondi S, Tarantino F, De Palma R, Marzocchi A

May 19, 2009

Percutaneous treatment of multivessel coronary disease in the drug eluting stent era: comparison of bare-metal stents, drug-eluting stents and a mixed approach in a large multicentre registry

Varani E, Saia F, Balducelli M, Guastaroba P, Marrozzini C, Tarantino F, Passerini F, Sangiorgio P, Percoco G, Grilli R, Marzocchi A, Maresta A

February 20, 2007

1

Latest news

STATE OF THE ART

Transcatheter treatment for tricuspid valve disease

This State-of-the-Art - by F. Praz et al - reviews the available transcatheter therapies, main criteria for patient and device selection, remaining uncertainties, and future directions

November 19, 2021

PCR London Valves Edition: state of the art on transcatheter treatment for tricuspid valve disease, a mini focus on TR; coronary access after TAVI and more…

November 19, 2021

EuroIntervention is now on Instagram

November 29, 2021

Long-term impact of OCT-assessed suboptimal stent deployment

Francesco Prati et al.

November 25, 2021

Percutaneous tricuspid valve annuloplasty: additional data and remaining questions

Nicole Karam et al.

November 23, 2021

Bioprosthetic valve fracture: haemodynamically effective but safe and clinically necessary?

Josep Rodés-Cabau et al.

November 23, 2021

Guidelines, consensus & position papers

consult the most recent published guidelines, consensus and position papers

November 29, 2021

Valvular disease